Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29, Yahoo Finance reports.
Corbus Pharmaceuticals Trading Up 11.0 %
Shares of Corbus Pharmaceuticals stock traded up $5.30 on Thursday, hitting $53.60. 377,665 shares of the company traded hands, compared to its average volume of 544,277. Corbus Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $61.90. The company has a market cap of $572.82 million, a P/E ratio of -7.77 and a beta of 2.59. The firm’s 50-day simple moving average is $50.70 and its 200 day simple moving average is $40.24.
Insider Buying and Selling at Corbus Pharmaceuticals
In other news, CEO Yuval Cohen sold 11,103 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $46.02, for a total value of $510,960.06. Following the transaction, the chief executive officer now owns 84,400 shares in the company, valued at $3,884,088. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 11,103 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $46.02, for a total value of $510,960.06. Following the completion of the transaction, the chief executive officer now directly owns 84,400 shares in the company, valued at approximately $3,884,088. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sean F. Moran sold 9,355 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $49.87, for a total transaction of $466,533.85. Following the transaction, the chief financial officer now owns 48,605 shares in the company, valued at approximately $2,423,931.35. The disclosure for this sale can be found here. Insiders sold a total of 51,733 shares of company stock worth $2,530,799 over the last three months. Company insiders own 4.00% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on Corbus Pharmaceuticals
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Featured Articles
- Five stocks we like better than Corbus Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Why Invest in 5G? How to Invest in 5G Stocks
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- What is the Nikkei 225 index?
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.